OR WAIT null SECS
Susan J. Schniepp is a fellow at Regulatory Compliance Associates, Inc. and a member of Pharmaceutical Technology's Editorial Advisory Board.
January 02, 2009
The USP public-comment process exists for a reason. Industry needs to take advantage. This article contains bonus online-exclusive material.
October 01, 2008
The growth and globalization of the pharmaceutical supply chain make risk assessment more important than ever for pharmaceutical manufacturers. The authors describe a program to identify, prioritize, mitigate, and communicate risks in manufacturer–supplier relationships.
August 06, 2008
Providing the right information upfront may ease new requirements to assess solvent levels.
July 02, 2008
October 02, 2004
The authors dispel common misinterpretations of the United States Pharmacopeia.